Technical Analysis for CMVLF - Cellectis Romainvil

Grade Last Price % Change Price Change
grade B 18.32 11.03% 1.8200
CMVLF closed up 11.03 percent on Wednesday, February 19, 2020, on 17 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical CMVLF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 11.03%
Narrow Range Bar Range Contraction 11.03%
Wide Bands Range Expansion 11.03%
Down 3 Days in a Row Weakness 11.03%
Gapped Down Weakness 11.03%
Narrow Range Bar Range Contraction 10.83%
Wide Bands Range Expansion 10.83%
Older signals for CMVLF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Biotechnology RTT Cancer Immunotherapy Cancer Immunotherapy Acute Myeloid Leukemia Immunotherapies Multiple Myeloma Leukemia Acute Lymphoblastic Leukemia Hematologic Malignancies Texas Md Anderson Cancer Center University Of Texas Tumors Of The Hematopoietic And Lymphoid Tissues Agricultural Biotechnology Harvard University Adoptive Cell Transfer Blastic Plasmacytoid Dendritic Cell Neoplasm Cellectis Immuno Oncology Products Liquid Tumors

Is CMVLF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 36.56
52 Week Low 9.15
Average Volume 602
200-Day Moving Average 22.2189
50-Day Moving Average 14.0363
20-Day Moving Average 13.8650
10-Day Moving Average 17.1690
Average True Range 1.0268
ADX 22.1
+DI 53.6598
-DI 35.6916
Chandelier Exit (Long, 3 ATRs ) 15.9196
Chandelier Exit (Short, 3 ATRs ) 12.2304
Upper Bollinger Band 21.0497
Lower Bollinger Band 6.6803
Percent B (%b) 0.81
BandWidth 103.6379
MACD Line 1.3171
MACD Signal Line 0.8124
MACD Histogram 0.5047
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.3200
Resistance 3 (R3) 18.3200 18.3200 18.3200
Resistance 2 (R2) 18.3200 18.3200 18.3200 18.3200
Resistance 1 (R1) 18.3200 18.3200 18.3200 18.3200 18.3200
Pivot Point 18.3200 18.3200 18.3200 18.3200 18.3200
Support 1 (S1) 18.3200 18.3200 18.3200 18.3200 18.3200
Support 2 (S2) 18.3200 18.3200 18.3200 18.3200
Support 3 (S3) 18.3200 18.3200 18.3200
Support 4 (S4) 18.3200